ArticleNature2023
Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 36 citations in OpenAlex.
- Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.International journal of radiation oncology, biology, physics · 2025Trial
- The BRCA1 coiled-coil domain is dispensable for suppression of tandem duplications and tolerance of FANCM loss.The EMBO journal · 2026Article
- Article
- PCNA-RECQL5-RPRD1B recruit repair components to stressed replication forks to promote survival of BRCA1-deficient cancer cells.Nucleic acids research · 2026Article
- Genome-wide association study identifies toll-like receptor four protein-mediated metabolic remodelling affecting gout pathogenesis.Journal of global health · 2026Observational
- Assessing the Clinical Relevance ofCurrent oncology (Toronto, Ont.) · 2026Article
- Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality.Molecules (Basel, Switzerland) · 2026Review
- ALK Knock-In Reporter Reveals APE1 as a Negative Regulator ofInternational journal of molecular sciences · 2026Article
- Choline metabolism drives metastasis in BRCA1-deficient ovarian cancers by activating FAM3C.Nature communications · 2026Article
- Decoding DNA metabolism and its clinical relevance through the lens of high-throughput sequencing assays.Medical review (2021) · 2026Review
- Pan-Cancer Genomic Scars of Alternative End Joining and Single-Strand Annealing.bioRxiv : the preprint server for biology · 2026Article
- Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.Cancer medicine · 2026Article
- New twist on BRCA1-mediated DNA recombination repair and tumor suppression.Trends in cell biology · 2026Review
- A breakage-replication/fusion process explains complex rearrangements and segmental DNA amplification.Nature genetics · 2026Article
- DNA shape and epigenomics distinguish the mechanistic origin of human genomic structural variations.Nucleic acids research · 2025Article
- Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer.Cancer discovery · 2025Article
- Review
- Long read sequencing reveals novel genomic and epigenomic alterations in repetitive regions of high grade serous ovarian cancer.Scientific reports · 2025Article
- Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 2 countries.
Jeremy Setton *Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kevin Hadi *Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Zi-Ning Choo *Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Katherine S KuchinDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Huasong TianDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Arnaud Da Cruz PaulaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joel RosieneDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8610-370X
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julie BehrDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Xiaotong YaoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-5140-6639
Aditya DeshpandeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Michael SigourosEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-0328-8359
Jyothi ManoharEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Jones T NauseefNew York Genome Center, New York, NY, USA.ORCID 0000-0003-2302-4171
Juan-Miguel MosqueraDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4666-6476
Olivier ElementoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8061-9617
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9927-1270
Nadeem RiazDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9873-5862
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2969-3173
Simon N PowellDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. powells@mskcc.org.ORCID 0000-0002-8183-4765
Marcin ImielińskiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. mski@mskilab.org.ORCID 0000-0002-2211-4741
Cornell University · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749
Abstract
Homologous recombination (HR) deficiency is associated with DNA rearrangements and cytogenetic aberrations
Indexed as
BRCA1 ProteinBRCA2 ProteinChromosome AberrationsDNA RepairNeoplasmsChromosome InversionCytogenetic AnalysisHomologous RecombinationHumansTranslocation, GeneticBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.